Drugs of Abuse Flashcards

(60 cards)

1
Q

DEA Schedule I

A

High Potential for Abuse
No acceptable use as a therapeutic in the US
Examples: LSD, Heroin, Marijuana

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

DEA Schedule II

A

High Potential for Abuse
Abuse may lead to sever psychological (addiction) or physical dependence
These drugs have accepted medical uses in the US
Examples: morphine, codeine, amphetamine, cocaine, barbituates

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

DEA Schedule III

A

Potential for abuse less than drugs in Schedules I and II
Abuse may lead to moderate or low physical dependence or high psychological dependence
Examples: codeine+acetaminophen, anabolic steroids

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

DEA Schedule IV

A

Low potential for abuse compared to the drugs in Schedule III
Abuse may lead to limited physical or psychological dependence relative to the drugs in Schedule III
Examples: benzodiazepines, tramadol

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

DEA Schedule V

A

Low potential for abuse relative to the drugs in Schedule IV

Examples: OTC cough medicines w/codeine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Cellular Tolerance

A

Adaptive response of cells to drug exposure
Major Mechanism: Occurs within seconds, hours, or days
Changes in receptors or cell signaling proteins
Receptors can be removed from the cell surface or trafficked to the cell surface
Synthesis of new receptors can be inhibited

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Metabolic Tolerance

A

Enhanced elimination rate of drug
Minor mechanism
Induction of drug metabolizing enzymes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Biological Theory of Addiction

A

Stimulation of the brain’s reward system

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Main Component of the Reward System

A

Mesocorticolimbic pathway: dopaminergic neurons from midbrain (ventral tegmental area) to the forebrain (nucleus accumbens and prefrontal cortex)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Physiological Dependence

A

Appearance of withdrawal symptoms when drug intake is stopped
Occurs with repeated/chronic use of the drug

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Impaired Control Over Substance Use Criteria

A
  1. Individual uses a substance in larger amounts or for longer period of time than intended
  2. Wants to cut down or quit but not able to
  3. Spends a lot of time obtaining and using a substance
  4. Craving: intense desire or urge to obtain the substance
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Social Impairment Criteria

A
  1. Failure to fulfill obligations at work, school, or home due to substance use
  2. Continues substance use despite negative social or interpersonal consequences
  3. Important social, occupational, or recreational activities are given up or reduced due to substance abuse
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Risk Use Criteria

A
  1. Recurrent substance use in situations that are physically hazardous
  2. Continues substance use despite known negative physical/psychological effects
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Pharmacological Criteria

A
  1. Appearance of tolerance: use requires markedly increased doses of substance to achieve the desired effect
  2. Appearance of withdrawal symptoms: Individual is likely to consume the substance to relieve the symptoms
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Opioids: Drug Effect

A

Activation of mu opioid receptors in medullary respiratory center, spinal and supraspinal sites mediating analgesia, enteric nerves

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Opioids: Acute Effects

A

Histamine release resulting in vasodilation, bronchoconstriction, hypotension
Potentially life-threatening respiratory depression

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Opioids: Tolerance/Withdrawal

A

Uncomfortable but not life-threatening symptoms: hyperalgesia, diarrhea, dilated pupils, hypertension, sweating, dysphoria, craving

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Opioids: Mechanism of Reward Pathway Activation

A

Activation of mu opioid receptors in reward pathway

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

CNS Depressants: Drug Effects

A

Ethanol: enhances GABA binding to GABA-A receptors, inhibits glutamate binding to NMDA receptor
Benzodiazepines: enhance GABA binding to GABA-A receptor
Barbituates: enhance GABA binding and directly activate GABA-A receptor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

CNS Depressants: Mechanism of Reward Pathway

A

Ethanol: inhibits glutamate binding to NMDA receptor, facilitates release of endogenous opioids in VTA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

CNS Depressants: Acute Effects/Toxicity

A

Potentially life-threatening respiratory depression with ethanol and barbiturates

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

CNS Depressants: Tolerance/Withdrawal

A

Sympathetically driven tremors, tachycardia, hypertension, sweating

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Stimulants: Drug Effect

A

Amphetamine and methamphetamine enhance synaptic release of DA
Cocaine blocks reuptake of DA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Stimulants: Acute Effects

A

Acute Effects: arousal, alertness, euphoria, increased HR and BP
Chronic Use can lead to hallucinations, violent behavior, psychosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Stimulants: Tolerance/Withdrawal
Reverse tolerance can be seen in some patients | Withdrawal may be mild: dysphoria, sleepiness, bradycardia, craving and depression
26
Nicotine: Drug Effects
Activation of central and peripheral acetylcholine receptors in reward pathway
27
Nicotine: Acute Effects/Toxicity
Stimulant effects: increased arousal, concentration Depressant effects: decreased anxiety
28
Nicotine: Tolerance/Withdrawal
Irritability, anxiety, dysphoria, difficulty concentrating, restlessness, increased appetite/weight gain
29
Cannabinoids: Drug Effect
Activation of cannabinoid receptors in brain and spinal cord
30
Cannabinoids: Acute Effects/Toxicity
Relaxation, increased appetite, psychedelic-like effects, sympathomimetic effects
31
Cannabinoids: Tolerance Withdrawal
Tolerance to acute effects develops quickly | Withdrawal: restlessness, irritability, depression, insomnia
32
Psychedelics: Drug Effect
Related to serotonin: agonists at 5HT, DA and adrenergic receptors Related to dopamine and amphetamines: induce 5HT and DA release; agonist 5HT, DA, and adrenergic receptors
33
Psychedelics: Acute Effects/Toxicity
Altered perception, hallucinations (mostly visual), altered mood
34
Psychedelics: Tolerance/Withdrawal
Minimal tolerance | Withdrawal: craving, confusion, anxiety, depression
35
Dissociatives: Drug Effects
Inhibits NMDA receptors
36
Dissociatives: Acute Effects/Toxicities
Analgesia, anesthesia, feelings of detachment, increased HR and BP Toxicities: hallucinations, delusions, psychosis, violent behavior High doses: seizures, coma, death
37
Disulfram: Clinical App and Mechanism
Alcohol aversion therapy Inhibits ALDH, leading to accumulation of acetaldehyde upon consumption
38
Disulfram: Adverse Reactions
Hepatotoxic | Can lead to respiratory depression, cardiovascular collapse, convulsions
39
Acamprosate, Topiramate: Clinical App and Mechanism
Alcohol addiction known to increase the activity of GABA-A receptors and inhibit glutamatergic NMDA receptor activity
40
Naloxone: Clinical App and Mechanism
Used in opioid overdose Inhibits mu opioid receptors in VTA of brain; SHORT ACTING
41
Naloxone: Side Effects
Cardiac arrhythmias, hepatotoxic, pulmonary edema, opioid withdrawal
42
Naltrexone: Clinical App
Anti-craving therapy for alcohol addiction Limited success in treating opioid dependency
43
Naltrexone: Mechanism of Action
Inhibits mu opioid receptors in VTA; LONG ACTING
44
Methadone: Clinical App
Used for detoxification and maintenance of opioid addiction
45
Methadone: Mechanism of Action
Agonist at mu opioid receptor; suppresses symptoms of craving and withdrawal
46
Methadone: Adverse Effects
Cardiac arrest due to long QT syndrome, respiratory arrest, constipation, nausea
47
LAAM: Clinical App
Maintenance therapy and detox for opioid addiction
48
LAAM: Mechanism of Action
Same as methadone but longer lasting so delivered 2-3/week
49
LAAM: Adverse Effects
Same as methadone
50
Buprenorphine: Clinical App
Maintenance and detox for opioid addiction
51
Buprenorphine: Mechanism of Action
Partial agonist at mu opioid receptor and antagonist at kappa opioid receptor; LONG ACTING
52
Buprenorphine: Adverse Effects
Respiratory depression, hypotension, dizziness, sedation, bradyarrythmias, tachyarrhytmias
53
Nicotine Replacement Therapy (NRT): Clinical App
Smoking cessation aid; multiple forms available
54
NRT: Mechanism of Action
Slower absorption and longer nicotine plasma levels, less rewarding and alleviating cravings
55
Bupropion: Clinical App
Smoking cessation aid
56
Buproprion: Mechanism of Action
Non-competitive antagonist of nicotinic acetylcholine receptors in reward pathway
57
Buproprion: Adverse Effects
Suicidal thoughts, erratic behavior, exacerbation of underlying psych illness
58
Varenicline: Clinical App
Smoking cessation aid, reduces cravings, prevents withdrawal
59
Varenicline: Mechanism of Action
Partial agonist at nicotinic acetylcholine receptors in VTA and nucleus accumbens
60
Varenicline: Adverse Effects
Suicidal thoughts, erratic/aggressive behavior, exacerbation of underlying psych illness